The Effect of Topical Application of Royal Jelly on Chemoradiotherapy-Induced Mucositis in Head and Neck Cancer: A Preliminary Study

Table 1

Patients’ profile.

Case	Group	Tumor site	Sex	Age (year)	TNM stage	IC	CRT
1	RJ	Larynx	M	59	T2N0M0	—	S-1
2	RJ	Oropharynx	M	84	T3N2cM0	—	S-1
3	RJ	Hypopharynx	M	62	TXN3M0	S1 + N	N + T
4	RJ	Hypopharynx	M	58	T1N3M0	S1 + N	N + T
5	RJ	Larynx	F	75	T2N0M0	—	S-1
6	RJ	Oropharynx	M	65	T4aN2bM0	—	CDDP
7	RJ	Hypopharynx	M	51	T2N2bM0	—	N + T
8	CONT	Hypopharynx	M	84	T2N0M0	—	S-1
9	CONT	Oropharynx	M	63	T1N2bM0	—	N + T
10	CONT	Oropharynx	M	62	T1N2aM0	—	CDDP
11	CONT	Oropharynx	M	65	T4aN0M0	S1 + N	N + T
12	CONT	Hypopharynx	M	66	T2N1M0	S1 + N	S-1
13	CONT	Maxillary sinus	M	78	T4aN0M0	—	CDDP

RJ: royal jelly, CONT: control, M: male, and F: female.
IC: induction chemotherapy.
CRT: chemoradiotherapy.
S1 + N: S1 + nedaplatin.
S1: S-1 regimen.
N + T: Weekly nedaplatin and docetaxel regimen.
CDDP: Cisplatin regimen.